CorMedix Conference Call Summary Company Overview - **Company**: CorMedix - **Focus**: Transitioned from a single product company (DefenCath) to a diversified specialty pharmaceutical company post-acquisition of Melinta in 2025, focusing on institutional settings of care with a portfolio primarily of injectable anti-infective drugs [3][4] Strategic Focus Areas - **Current Strategy**: Aiming to diversify beyond renal space and focus on various therapeutic areas within institutional care settings [4] - **Development Pipeline**: - **REZZAYO**: In phase 3 studies for prophylaxis of invasive fungal infections, with data readout expected in mid-to-late second quarter [4] - **DefenCath**: In phase 3 for prevention of CLABSI in patients receiving total parenteral nutrition (TPN), targeted for completion in early 2027 [5] Key Product Insights - **DefenCath**: - Demonstrated a 70% reduction in CRBSIs and hospitalizations in clinical studies [7][8] - Unique reimbursement model (TDAPA) allows for a two-year window for buy and bill reimbursement, transitioning to bundled payments [9] - Focus on stabilizing patient utilization and growth strategies for Medicare Advantage patients [10][16] - **REZZAYO**: - Long-acting echinocandin with a total addressable market of $250-$350 million, currently indicated for treatment of Candida infections [24] - Differentiation potential in prophylaxis against invasive fungal disease, with a focus on reducing drug-drug interactions and hepatotoxicity compared to standard care [26][40] Market Opportunities - **DefenCath in TPN**: Addressable market estimated at $500-$750 million, with high unmet needs in infection prevention for patients on TPN [46][47] - **REZZAYO Prophylaxis**: Potential market size of $500 million for allogeneic bone marrow transplant patients, with additional opportunities in solid organ transplants [40][41] Financial Position - **Cash Position**: Approximately $150 million in cash with zero net debt, expected to generate cash flow through 2026 [55] - **Stock Buyback**: Announced a $70 million stock repurchase program to enhance shareholder value [55] Contracting and Reimbursement Strategy - **Dialysis Operators**: Agreements structured to accommodate potential reimbursement challenges during the TDAPA transition [63] - **Medicare Advantage**: Early discussions ongoing, with expectations for positive payer feedback [43] Investor Insights - **Market Valuation**: Currently valued at 4.5x forward EBITDA, significantly below peers (9x-14x), indicating potential undervaluation of REZZAYO and DefenCath [68] - **Future Growth Catalysts**: Anticipated updates on clinical data and market strategies expected to align company valuation with operational strength [68] Conclusion - CorMedix is positioned for growth with a diversified product pipeline and strategic focus on institutional care settings. The upcoming clinical data for REZZAYO and DefenCath, along with a solid financial foundation, presents a compelling investment opportunity.

分组1 - CorMedix reported quarterly earnings of $0.61 per share, missing the Zacks Consensus Estimate of $0.86 per share, compared to earnings of $0.22 per share a year ago, representing an earnings surprise of -29.07% [1] - The company posted revenues of $128.62 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.03%, and this is a significant increase from year-ago revenues of $31.21 million [2] - CorMedix shares have lost about 38.8% since the beginning of the year, while the S&P 500 has gained 0.4% [3] 分组2 - The current consensus EPS estimate for the coming quarter is $0.74 on revenues of $111.85 million, and for the current fiscal year, it is $1.30 on revenues of $307.45 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 46% of over 250 Zacks industries, indicating that the industry outlook can materially impact stock performance [8] - CorMedix has a Zacks Rank of 5 (Strong Sell), suggesting that the shares are expected to underperform the market in the near future [6]

Financial Data and Key Metrics Changes - In Q4 2025, net revenue reached $128.6 million, a significant increase from $31.2 million in Q4 2024, primarily driven by DefenCath's contribution of $91.2 million and Melinta's contribution of $37.4 million [16] - For the full year 2025, total revenue on a pro forma basis was $401.3 million, aligning with previously established guidance [16] - The company reported a net income of $14 million in Q4 2025, impacted by a tax expense of $42.4 million, mostly non-cash [18] - Adjusted EBITDA for Q4 was $77.2 million, reflecting modest growth quarter-over-quarter [19] - Cash and cash equivalents at the end of Q4 were $148.5 million, supported by strong operating cash flow of nearly $100 million during the quarter [20] Business Line Data and Key Metrics Changes - DefenCath generated $258.8 million in net sales for the full year 2025, with peak sales of just under $260 million achieved [5][16] - The Melinta portfolio contributed $37.4 million in Q4 2025, marking the first full reporting period post-acquisition [16] - Operating expenses in Q4 2025 were $48.2 million, up from $17.1 million in the prior year, reflecting the expanded cost structure due to the Melinta acquisition [17] Market Data and Key Metrics Changes - The company is focusing on maintaining patient utilization rates for DefenCath in outpatient hemodialysis as it transitions to a bundled add-on reimbursement model starting July 1, 2026 [6] - The estimated market opportunity for REZZAYO is approximately $2.5 billion across its indications, while DefenCath and TPN are estimated between $500 million and $750 million [9] Company Strategy and Development Direction - The company aims to achieve a target synergy of $35 million from the Melinta acquisition during Q4 2025 and is focused on integrating operations for long-term sustainable growth [5] - CorMedix is actively engaging with multiple Medicare Advantage providers and new potential customers for DefenCath, REZZAYO, MINOCIN, and BAXDELA [8] - The company has announced a share repurchase program, indicating confidence in its financial flexibility and growth potential [21] Management's Comments on Operating Environment and Future Outlook - Management views 2025 as a transformational year and anticipates 2026 to be transitional, setting the stage for long-term growth in 2027 and beyond [21] - The company is optimistic about the potential for increased Medicare provider reimbursement in 2027, which could lead to a higher net selling price for DefenCath [7] - Management is confident in the outlook for 2026 and the path to future growth and sustained profitability [21] Other Important Information - The company completed its first analyst R&D day, focusing on educating stakeholders about the market opportunity for REZZAYO and its pipeline assets [9] - The Nutriguard clinical study for DefenCath is approximately 30% enrolled, with completion anticipated in early 2027 [14] Q&A Session Summary Question: Update on dialysis customer conversations regarding DefenCath - Management indicated that conversations are progressing well, focusing on preserving patient utilization and negotiating pricing structures for 2026 and 2027 [23] Question: Clinical significance of REZZAYO phase III data - Management highlighted the importance of various success metrics in the data, which will guide marketing strategies and discussions with payers [24][25] Question: Developments on TDAPA extension bills - Management noted that timing is uncertain due to legislative complexities and current global events, but they are actively working on the issue [29][30] Question: Inpatient opportunity with DefenCath and Melinta product portfolio - Management discussed the current customer mix and potential growth opportunities, emphasizing the importance of onboarding additional customers [33][41]

Financial Data and Key Metrics Changes - In Q4 2025, net revenue reached $128.6 million, a significant increase from $31.2 million in Q4 2024, primarily driven by DefenCath's contribution of $91.2 million and Melinta's contribution of $37.4 million [16][17] - For the full year 2025, total revenue on a pro forma basis was $401.3 million, aligning with previously established guidance [16] - The company reported a net income of $14 million in Q4 2025, impacted by a tax expense of $42.4 million, mostly non-cash [18][19] - Adjusted EBITDA for Q4 was $77.2 million, reflecting modest growth quarter-over-quarter [19][20] - Cash and cash equivalents at the end of Q4 were $148.5 million, supported by strong operating cash flow of nearly $100 million during the quarter [20] Business Line Data and Key Metrics Changes - DefenCath generated $258.8 million in net sales for the full year 2025, with peak sales of just under $260 million achieved [5][16] - The Melinta portfolio contributed $37.4 million in Q4 2025, marking its first full reporting period post-acquisition [16] Market Data and Key Metrics Changes - The company anticipates a revenue concentration for DefenCath to be front-loaded in the first half of 2026, with expected price erosion in the latter half due to the transition to a bundled add-on reimbursement mechanism [6][7] - The estimated market opportunity for REZZAYO is approximately $2.5 billion across its indications, while DefenCath and TPN are estimated between $500 million and $750 million [9] Company Strategy and Development Direction - The company is focused on maintaining patient utilization rates for DefenCath and negotiating pricing structures for 2026 and 2027 [6][7] - The acquisition of Melinta Therapeutics is seen as a strategic move to enhance growth, with a focus on integrating operations and achieving synergies [5][10] - The company is actively pursuing discussions with Medicare Advantage providers and new customers for DefenCath [8] Management's Comments on Operating Environment and Future Outlook - Management views 2025 as a transformational year and expects 2026 to be transitional, setting the stage for long-term sustainable growth [21] - The company remains confident in its financial flexibility and commercial momentum, positioning itself for both organic and inorganic growth opportunities [21] Other Important Information - The company completed its first analyst R&D day, focusing on educating stakeholders about the market opportunity for REZZAYO and its pipeline assets [8][9] - The phase 3 ReSPECT study for REZZAYO is on track for top-line data release in Q2 2026 [11][12] Q&A Session Summary Question: Update on dialysis customer conversations regarding DefenCath pricing - Management indicated that conversations are progressing well, focusing on preserving patient utilization and negotiating pricing structures for 2027 [23] Question: Clinical significance of REZZAYO phase 3 data - Management highlighted the importance of pathogen data and secondary endpoints in guiding commercial utility and marketing strategies [24][25] Question: Developments on TDAPA extension bills - Management noted that timing is uncertain due to legislative complexities and current global events, but they are actively working on the issue [29][30] Question: Inpatient opportunity with DefenCath and Melinta product portfolio - Management discussed the current customer mix and potential growth opportunities, emphasizing the importance of onboarding new customers [33][41]

Financial Data and Key Metrics Changes - In Q4 2025, net revenue reached $128.6 million, a significant increase from $31.2 million in Q4 2024, primarily driven by DefenCath's contribution of $91.2 million and Melinta's portfolio contribution of $37.4 million [16][17] - For the full year 2025, total revenue on a pro forma basis was $401.3 million, aligning with previously established guidance [16] - The company reported a net income of $14 million in Q4 2025, impacted by a tax expense of $42.4 million, mostly non-cash [18][19] - Adjusted EBITDA for Q4 was $77.2 million, reflecting modest growth quarter-over-quarter [19] Business Line Data and Key Metrics Changes - DefenCath generated $258.8 million in net sales for the full year 2025 [17] - The operating expenses for Q4 2025 were $48.2 million, up from $17.1 million in the prior year, reflecting the expanded cost structure post-Melinta acquisition [17] Market Data and Key Metrics Changes - The company is focusing on maintaining patient utilization rates for DefenCath in outpatient hemodialysis, especially as reimbursement transitions to a bundled add-on mechanism starting July 1, 2026 [6][7] - The guidance for DefenCath in 2026 is set at $150 million-$170 million, with 2027 guidance at $100 million-$125 million [6][8] Company Strategy and Development Direction - The acquisition of Melinta Therapeutics is seen as a significant growth opportunity, adding durable products like MINOCIN and VABOMERE to the portfolio [11] - The company is actively pursuing discussions with Medicare Advantage providers and new customers for DefenCath, REZZAYO, MINOCIN, and BAXDELA [9] - 2026 is expected to be a transitional year, with a focus on new catalysts and value drivers, particularly the phase 3 ReSPECT data for REZZAYO [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the post-TDAPA environment and maintain growth through strategic pricing and customer negotiations [6][23] - The company is optimistic about the potential for increased Medicare provider reimbursement in 2027, which could lead to a higher net selling price [7] Other Important Information - The company has expanded its workforce significantly, growing from approximately 100 to just under 200 employees, to support growth and operational needs [17] - The company has initiated a share repurchase program, indicating confidence in its financial position and future growth prospects [21] Q&A Session Summary Question: Update on dialysis customer conversations and pricing for DefenCath - Management indicated that conversations are progressing well, focusing on preserving patient utilization and negotiating pricing structures for 2026 and beyond [23] Question: Clinical significance of REZZAYO phase 3 data - Management highlighted that the data will guide commercial utility and marketing strategies, with a focus on pathogen data and secondary endpoints [24][25] Question: Developments on TDAPA extension bills and partnerships - Management noted ongoing efforts with legislators and other companies, but timing remains uncertain due to external factors [29][30] Question: Inpatient opportunity with DefenCath and Melinta product growth - Management discussed the current customer mix and potential growth from mid-sized operators, emphasizing the importance of onboarding new customers [33][41]

Product Development and Acquisitions - DefenCath, launched in 2024, is the first FDA-approved antimicrobial catheter lock solution, reducing CRBSI risk by up to 71% in clinical studies[219]. - The acquisition of Melinta was completed on August 29, 2025, for a total cash consideration of $260 million and 3.3 million common shares, expanding the company's product portfolio significantly[224]. - Melinta's financial results will be included in consolidated statements starting from the acquisition date, affecting comparability with prior periods[223]. - The company has a partnership with BARDA, with total funding potential of up to $144.6 million for the development of BAXDELA and VABOMERE[236]. - The company is obligated to make contingent payments to former Melinta equity holders upon FDA marketing approval of REZZAYO, with potential payments including $20 million for candida labeling and $2.5 million each for aspergillus and pneumocystis labeling[283]. - The company assumed commitments under the REZZAYO License Agreement, including a regulatory milestone payment of $30 million to $40 million upon FDA approval for the REZZAYO Second Indication[280]. - The purchase price of Melinta included contingent consideration related to tiered royalty payments based on future net sales and regulatory milestones[289]. - The company evaluates the need to remeasure contingent consideration obligations at the end of each reporting period, which may impact consolidated results of operations[290]. Financial Performance - Revenue for the year ended December 31, 2025 was $311.7 million, an increase of $268.2 million, or 617% compared to $43.5 million in 2024[252]. - Product sales for 2025 were $304.3 million, a 600% increase from $43.5 million in 2024, primarily driven by sales of DefenCath[253]. - Cost of revenue for 2025 was $22.1 million, an increase of $19.1 million, or 628% from $3.0 million in 2024[256]. - Net income for 2025 was $163.1 million, compared to a net loss of $17.9 million in 2024[269]. - Net cash provided by operating activities was $175.0 million in 2025, compared to net cash used of $50.6 million in 2024[269]. - The company achieved profitability in 2025, primarily driven by product sales of DefenCath[268]. - Total cash, cash equivalents, and short-term investments as of December 31, 2025, was $148.5 million, up from $51.7 million in 2024[272]. - The company expects to fund operations for at least twelve months from the issuance of these financial statements[275]. Expenses and Liabilities - Research and development expenses are incurred for drug development activities, with costs expensed as incurred, reflecting the high uncertainty in clinical trials[238][239]. - General and administrative expenses include costs related to executive functions, merger-related costs, and professional fees, all expensed as incurred[242]. - Research and development expenses rose to $19.3 million in 2025, a 390% increase from $3.9 million in 2024[259]. - General and administrative expenses increased to $68.2 million, up 128% from $30.0 million in 2024[261]. - As of December 31, 2025, the company had $12.4 million in accrued Medicaid rebates, reflecting the balance recorded for the Melinta Portfolio[285]. - A change in estimate for Medicaid rebates negatively impacted net sales and net income by $1.7 million for the year ended December 31, 2025, affecting earnings per share by $0.02[286]. - The company recorded $18.3 million in accrued returns allowance as of December 31, 2025, including the balance for the Melinta Portfolio[287]. - The company recognized an income tax benefit of $61.5 million for the year ended December 31, 2025, due to the expected utilization of historical federal NOLs[288]. - The total cost for API deliveries from the CMO for VABOMERE is €5.9 million, subject to inflation adjustments[281]. - The company has a total net obligation of $2.3 million related to a three-year agreement with Syneos Health, with expected complete settlement in Q1 2026[282]. Reimbursement and Pricing - The TDAPA reimbursement for DefenCath began on July 1, 2024, providing temporary additional payments for five years, with a projected decline in net pricing expected in Q3 and Q4 of 2026[220][221]. - Revenue from product sales includes DefenCath and the Melinta portfolio, recognized when control of the product is obtained by customers[233].

Core Insights - CorMedix Inc. reported a net revenue of $128.6 million for Q4 2025, with a full-year pro forma revenue of $401.3 million, reflecting significant growth compared to the previous year [1][4][8] - The company achieved a net income of $14.0 million in Q4 2025, with an adjusted EBITDA of $77.2 million, indicating strong operational performance [1][7][8] - CorMedix is focused on expanding patient access to its product DefenCath and has completed the acquisition of Melinta, which is expected to enhance its product portfolio [3][4] Financial Highlights - Q4 2025 net revenue included $91.2 million from DefenCath sales and $37.4 million from the Melinta portfolio, marking an increase from $31.2 million in Q4 2024 [4][5] - Total operating expenses for Q4 2025 were $48.2 million, a significant increase from $17.1 million in Q4 2024, primarily due to the Melinta acquisition and associated costs [5][9] - For the full year 2025, CorMedix reported total revenue of $311.7 million, with net sales of DefenCath at $258.8 million and net revenue from Melinta at $52.9 million [8][9] Operational Developments - The company has initiated a share repurchase program authorizing up to $75 million of its common stock [5] - CorMedix anticipates clinical data from the Phase 3 ReSPECT study of REZZAYO in Q2 2026, which is crucial for its growth strategy [5][14] - The ongoing Phase 3 study of taurolidine/heparin catheter lock solution in TPN patients is expected to complete enrollment in the first half of 2027 [5][14] Cash Position - As of December 31, 2025, CorMedix had cash and short-term investments totaling $148.5 million, excluding restricted cash [10][22]

Core Insights - CorMedix Therapeutics will report its financial results for Q4 and full year 2025 on March 5, 2026, before market opens and will host a corporate update conference call at 8:30 AM ET [1][2] Company Overview - CorMedix Therapeutics is focused on developing and commercializing therapeutic products for life-threatening diseases and conditions [3] - The company is commercializing DefenCath for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis [3] - Following the acquisition of Melinta Therapeutics in August 2025, CorMedix is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV™, BAXDELA, and KIMYRSA [3] Clinical Studies and Developments - CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations [4] - The company intends to develop DefenCath as a catheter lock solution for other patient populations [4] - REZZAYO is approved for treating candidemia and invasive candidiasis in adults, with a Phase III study ongoing for prophylaxis of invasive fungal disease in adult patients undergoing allogeneic bone marrow transplantation, with topline results expected in Q2 2026 [4]

Core Insights - CorMedix (CRMD) and Theravance Biopharma (TBPH) are small-cap biopharmaceutical companies with market caps under $1 billion, focusing on commercialization and expansion of key therapies, presenting high-risk but potential high-reward investment opportunities [1] CorMedix (CRMD) - CorMedix's lead product, DefenCath, received FDA approval in late 2023 as the first antimicrobial catheter lock solution in the U.S., aimed at reducing catheter-related bloodstream infections in kidney failure patients undergoing hemodialysis [2] - DefenCath is the first approved product in CorMedix's portfolio, launched in 2024, and has seen strong market adoption [5] - Preliminary fourth-quarter and full-year 2025 results show net revenues of approximately $127 million and $310 million, respectively, driven by DefenCath and early contributions from the Melinta portfolio [6] - CorMedix plans to diversify revenues through the $300 million acquisition of Melinta Therapeutics, adding seven approved therapies to its portfolio [6] - Management's guidance for 2026 revenue is $300-$320 million, with projected DefenCath revenues of $100-$140 million for 2027, indicating a conservative growth outlook [7] Theravance Biopharma (TBPH) - Theravance collaborates with Viatris to develop and commercialize Yupelri, a nebulized treatment for COPD, sharing profits where Theravance receives 35% [3][9] - Yupelri is recognized as a cornerstone of maintenance therapy for COPD, providing consistent lung function improvement [10] - Revenues from the Viatris collaboration rose 18.5% year-over-year in the first nine months of 2025, contributing positively to Theravance's financials [11] - Theravance's balance sheet was strengthened by a $225 million royalty sale of Trelegy, extending its cash runway for pipeline development [13] - The company is developing ampreloxetine for neurogenic orthostatic hypotension, with top-line data expected in Q1 2026 [12] Financial Estimates and Performance - The Zacks Consensus Estimate for CorMedix's 2025 sales implies a year-over-year increase of around 614%, but EPS estimates have trended downward [15] - Theravance's 2025 sales estimate implies a year-over-year increase of around 65%, with EPS currently pegged at 24 cents [15] - In the past six months, CRMD shares have declined by 48.9%, while TBPH shares have increased by 39.8%, outperforming the industry [20] - Theravance's shares trade at a higher price-to-book ratio of 4.19 compared to CorMedix's 1.48, indicating a more expensive valuation [23] Investment Outlook - Theravance Biopharma is viewed as a better investment option due to its balanced risk-reward profile, diversified revenue streams, and strengthened cash position following the royalty sale [24][27] - CorMedix's reliance on DefenCath and conservative growth outlook presents challenges, making it a less favorable option compared to Theravance [28]

Core Viewpoint - Investors are expected to focus on the sales performance of CorMedix's lead product, DefenCath, during the upcoming fourth-quarter and full-year 2025 results report, with sales estimates at $127.3 million and earnings at 86 cents per share [1] Sales Performance - CorMedix's preliminary fourth-quarter sales are approximately $127 million, reflecting strong momentum from DefenCath and contributions from the Melinta portfolio [5][7] - The company anticipates 2026 revenues of $300-$320 million, with DefenCath sales expected to be weighted towards early 2026 [10] Earnings Estimates - The Zacks Consensus Estimate for 2025 EPS has decreased from $2.82 to $2.78 over the past 30 days, while the estimate for 2026 has dropped from $1.78 to $1.30 [1] - CorMedix has a positive earnings surprise history, beating estimates in the last four quarters with an average surprise of 27.04% [2][3] Product Insights - DefenCath is the first and only antimicrobial catheter lock solution approved in the U.S., aimed at reducing catheter-related bloodstream infections in patients undergoing chronic hemodialysis [6] - The product's sales are driven by strong market adoption, particularly among outpatient dialysis customers [8] Competitive Landscape - CorMedix faces significant competition from established players in the heparin market, including Pfizer, Amphastar Pharmaceuticals, and others, which could impact its market position and growth prospects [14][15] - The company’s reliance on DefenCath for growth may pose risks, especially if competitors target the same market segment [21] Valuation and Market Performance - CorMedix shares have declined by 48.8% over the past six months, underperforming the industry growth of 22.9% [12] - The stock is currently trading at a price/book ratio of 1.48, which is lower than the industry average of 3.78 [13]